Medicines based on red blood cell extracellular vesicles (RBCEVs), for the delivery of novel therapeutic modalities that include nucleic acids
Also RD pulmonary diseases, cancer
Carmine Therapeutics is developing non-viral gene therapies based on red blood cell extracellular vesicles (RBCEVs). RCVEVs are physiologically produced by red blood cells in large quantities and are highly amenable to manipulations such as addition of nucleic acid. These unique properties of RBCEVs make them ideally suited for gene therapy since they are biocompatible and readily available. Carmine is using their proprietary Red Cell EV Gene Therapy (REGENT®) platform to generate a pipeline of next-generation disease-modifying gene therapies for a broad spectrum of diseases. The REGENT platform offers the potential to deliver therapeutic payloads to a broad array of tissues such as the central nervous system and offers the ability to control the intracellular immune response.